Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alnylam Pharmaceuticals, U.S.
Study results from Alnylam Pharmaceuticals, Inc. provide new insights into RNA research
November 7th, 2006
Fresh data on rna research are presented in the report "Therapeutic potential of RNA interference for neurological disorders. During the past decade, numerous molecular mediators of neurodegenerative diseases and neurological disorders have been identified and validated, yet few novel therapies have emerged and the unmet medical needs remain high. These molecular mediators belong to target classes such as ion channels, neurotransmitters and neurotransmitter receptors, cytokines, growth factors, enzymes and other proteins," scientists in the United States report. "In some cases, substantial pre-clinical validation exists, but the molecular target has not been readily...
Source: Drug Law Weekly (2006-11-07)
|
